ОСОБЛИВОСТІ ГУМОРАЛЬНОГО ІМУНІТЕТУ ПРИ COVID-19 ТА ПЕРСПЕКТИВИ ВИКОРИСТАННЯ ПРОТИВІРУСНИХ АНТИТІЛ В КЛІНІЧНІЙ ПРАКТИЦІ (ОГЛЯД ЛІТЕРАТУРИ)

  • Mykola Lisianyi Head of the Department of Neuroimmunology, Corresponding Member of NAMNU, professor, Institute of Neurosurgery
Keywords: COVID -19 infection, immunity, neutralizing antibodies, immune drugs from convalescent blood

Abstract

The role of both cellular and humoral immune responses in the pathogenesis of COVID-19 is ambiguous and controversial. The presented literature review analyzes two views on this problem, namely the protective and stimulating viral infection (immune-pathological) role of various immune cells, especially antibodies. Data on the direction and level of neutralizing and non-neutralizing antibodies in the blood of patients, convalescents and healthy individuals and it is noted that up to 30-50% of patients have low levels of virus neutralizing antibodies, which complicates the use of antibodies for prevention and treatment of severe diseases. It is characterized by antigen-specific and nonspecific mechanisms of action of antibodies in corona infection, which differently affect the course of the disease. The review briefly discusses the problems associated with obtaining and using different types of monoclonal antibodies to treat critically ill patients. The article concludes that immune drugs from convalescent blood, which contains a high level of neutralizing antibodies, are currently the specific method of treatment for COVID -19.

References

1. Задорожна В.І. Винник Н.П. Корона вірус 2019 – nCOV: нові виклики охороні здоров’я та людству. Інфекційні хвороби 2020. №2 с.1-9. doi: 10.11603/1681-
2727.2020.1.11091 . Zadorozhna VI Vinnik NP Crown Virus 2019 – nCOV: New Challenges for Health and Humanity. Infectious diseases 2020. №2 p.1-9. doi: 10.11603/ 1681- 2727.2020.1.11091
2. Zost S.J., Gilchuk P., Case J.B., Binshtein E., Chen R.E., Reidy J.X., Trivette A., Nargi R.S., Sutton R.E., Suryadevara N., Williamson L.E., Chen E.C., Jones T., Day S., Myers L., Hassan A.O., Kafai N.M., Winkler E.S., Fox J.M., Steinhardt J.J., Ren K., Loo Y.-M., Kallewaard N.L., Martinez D.R., Schäfer A., Gralinski L.E., Baric R.S., Thackray L.B., Diamond M.S., Carnahan R.H., & Crowe Jr. J.E. (2020). Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals. bioRxiv., Preprint. 2020 May 22. doi:10.1101/2020.05.22.111005. PMCID: PMC7263556; PMID: 32511409.
3. van Griensven, J, Edwards, T, de Lamballerie, X, Semple, MG, Gallian, P, Baize, S, Horby, PW, Raoul, H, Magassouba, N, Antierens, A, Lomas, C, Faye, O, Sall, AA, Fransen, K, Buyze, J, Ravinetto, R, Tiberghien, P, Claeys, Y, De Crop, M, Lynen, L, Bah. EI, Smith. PG, Delamou, A, De Weggheleire, A, & Haba, N. (2016). Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med., 374, 33-42. doi:10.1056/NEJMoa1511812.PMID:26735992.
4. Long, Q-X, Deng, H-J, Chen, J, Hu, J, Liu, B-Z, Liao, P, Lin, Y, Yu, L-H, Mo, Z, Xu, Y-Y, Gong, F, Wu, G-C, Zhang, X-X, Chen, Y-K, Li, Z-J, Wang, K, Zhang, X-L, Tian, W-G, Niu, C-C, Yang, Q-J, Xiang, J-L, Du, H-X, Liu, H-W, Lang, C, Luo, X-H, Wu, S-B, Cui, X-P, Zhou, Z, Wang, J, Xue, C-J, Li, X-F, Wang, L, Tang, X-J, Zhang, Y, Qiu, J-F, Liu, X-M, Li, J-J, Zhang, D-C, Zhang, F, Cai, X-F, Wang, D, Hu, Y, Ren, J-H, Tang, N, Liu, P, Li, Q, & Huang, A-L. (2020). Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. medRxiv., [published online ahead of print March 20, 2020]. doi:10.1101/2020.03.18.20038018.5. Xiang, F, Wang, X, He, X, Peng, Z, Yang, B, Zhang, J, Zhou, Q, Ye, H, Ma, Y, Li, H, Wei, X, Cai, P, & Ma, WL. (2020). Antibody Detection and Dynamic Characteristics in Patients with COVID-19. Clin Infect Dis., ciaa461. doi:10.1093/cid/ciaa461. Online ahead of print.PMID: 32306047.
6. Suhandynata, RT, Hoffman, MA, Kelner, MJ, McLawhon, RW, Reed, SL, & Fitzgerald, RL. (2020). Longitudinal Monitoring of SARSCoV- 2 IgM and IgG Seropositivity to Detect COVID-19. J Appl Lab Med. PMID: 32428207;PMCID: PMC7313967. DOI:10.1093/jalm/jfaa079.
7. Hung, IF, Cheng, VC, Li, X, Tam, AR, Hung, DL, Chiu, KH, Yip, CC, Cai, JP, Ho, DT, Wong, SC, Leung, SS, Chu, MY, Tang, MO, Chen, JH, Poon, RW, Fung, AY, Zhang, RR, Yan, EY, Chen, LL, Choi, CY, Leung, KH, Chung, TW, Lam, SH, Lam, TP, Chan, JF, Chan, KH, Wu, TC, Ho, PL, Chan, JW, Lau, CS, To, KK, & Yuen, KY. (2020). SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series. Lancet Infect Dis., S1473-3099(20)30364-9.
PMID: 32539986; PMCID: PMC7292581. DOI:10.1016/S1473-3099(20)30364-9.
8. Ng, D, Goldgof, G, Shy, B, Levine, A, Balcerek, J, Bapat, SP, Prostko, J, Rodgers, M, Coller, K, Pearce, S, Franz, S, Du, L, Stone, M, Pillai, S, Sotomayor-Gonzalez, A, Servellita, V, Sanchez-San Martin, C, Granados, A, Glasner, DR, Han, LM, Truong, K, Akagi, N, Nguyen, DN, Neumann, N, Qazi, D, Hsu, E, Gu, W, Santos, YA, Custer, B, Green, V, Williamson, P, Hills, NK, Lu, CM, Whitman, JD, Stramer, S, Wang, C, Reyes, K, Hakim, J, Sujishi, K, Alazzeh, F, Pharm, L, Oon, C-Y, Miller, S, Kurtz, T, Hackett, J, Simmons, G, Busch, MP, & Chiu, CY. (2020). SARS-CoV-2 Seroprevalence and Neutralizing Activity in Donor and Patient Blood From the San Francisco Bay Area. medRxiv, 2020 May 25. Preprint. PMID:32511477; PMCID: PMC7273245. DOI:10.1101/2020.05.19.20107482.
9. Wrapp, D, Wang, N, Corbett, KS, Goldsmith, JA, Hsieh, CL, Abiona, O, Graham, BS, & McLellan, JS. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483), 1260-1263. doi:10.1126/science.abb2507. PMID: 32075877.
10. Walls, AC, Park, YJ, Tortorici, MA, Wall, A, McGuire, AT, & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2), 281-292. e6. doi: 10.1016/j.cell.2020.02.058. PMID:32155444; PMCID: PMC7102599.
11. Li, F. (2016). Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol., 3(1), 237-261. doi: 10.1146/annurevvirology-110615-042301. PMID: 27578435.
12. Shang, J, Ye, G, Shi, K, Wan, Y, Luo, C, Aihara, H, Geng, Q, Auerbach, A, & Li, F. (2020). Structural basis of receptor recognition by SARS-CoV-2. Nature, 581(7807), 221-224. doi: 10.1038/s41586-020-2179-y. PMID:32225175.
13. Jiang, S, Hillyer, C, & Du, L. (2020). Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol., 41(5), 355-359. doi: 10.1016/j.it.2020.03.007. PMID: 32249063.
14. Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA. Bianchi S, Jaconi S, Culap K, Zatta F, Marco AD, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veesler D, & Corti D. (2020). Structural and functional analysis of a potent Sarbecovirus neutralizing antibody. bioRxiv, 2020 Apr 9; 2020.04.07.023903. doi: 10.1101/2020.04.07.023903. Preprint. PMID: 32511354; PMCID: PMC7255795.
15. Tian, X, Li, C, Huang, A, Xia, S, Lu, S, Shi, Z, Lu, L, Jiang, S, Yang, Z, Wu, Y, & Ying, T. (2020). Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect., 9, 382-385. doi: 10.1080/22221751.2020.1729069. PubMed: 32065055.
16. Kannan, S, Shaik Syed Ali, P, Sheeza, A, & Hemalatha, K. (2020). COVID-19 (Novel Coronavirus 2019) - Recent Trends. Eur Rev Med Pharmacol Sci, 24(4), 2006-2011. doi:10.26355/eurrev_202002_20378. PMID:32141569.
17. Lou, B, Li, TD, Zheng, SF, Su, YY, Li, ZY, Liu, W, Yu, F, Ge, SX, Zou, QD, Yuan, Q, Lin, S, Hong, CM, Yao, XY, Zhang, XJ, Wu, DH, Zhou, GL, Hou, WH, Li, TT, Zhang, YL, Zhang, SY, Fan, J, Zhang, J, Xia, NS, & Chen Y. (2020). Serology characteristics of SARSCoV-2 infection since the exposure and post symptoms onset. Eur Respir J, 56(1). doi:10.1183/13993003.00763-2020. Online ahead of print. PMID: 32430429.
18. Choe, PG, Kang, CK, Suh, HJ, Jung, J, Kang, E, Lee, SY, Song, KH, Kim, HB, Kim, NJ, Park, WB, Kim, ES, & Oh, MD. (2020). Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. Emerg Infect Dis., 26(10). doi: 10.3201/eid2610.202211. Online ahead of print. PMID: 32579877.19. Zohar, T, & Alter, G. (2020). Dissecting antibody-mediated protection against SARSCoV-2. Nat Rev Immunol., 20(7), 392-394. doi: 10.1038/s41577-020-0359-5. PMID:32514035
20. Chan, KH, Chan, JF, Tse, H, Chen, H, Lau, CC, Cai, JP, Tsang, AK, Xiao, X, To, KK, Lau, SK, Woo, PC, Zheng, BJ, Wang, M, & Yuen, KY. (2013). Cross-reactive antibodies in convalescent SARS patients ‘sera against the emerging novel human coronavirus. J Infect., 67(2), 130-40. PMID: 23583636; PMCID: PMC7112694.
DOI: 10.1016/j.jinf.2013.03.015.
21. Liu, W, Fontanet, A, Zhang, PH, Zhan, L, Xin, ZT, Baril, L, Tang, F, Lv, H, Cao, WC. (2006). Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis., 193(6), 792-5. doi: 10.1086/500469. PMID:16479513; PMCID: PMC7109932.
22. Cameron, MJ, Ran, L, Xu, L, Danesh, A, Bermejo-Martin, JF, Cameron, CM, Muller, MP, Gold, WL, Richardson, SE, Poutanen, SM, Willey, BM, DeVries, ME, Fang, Y, Seneviratne, C, Bosinger, SE, Persad, D, Wilkinson, P, Greller, LD, Somogyi, R, Humar, A, Keshavjee, S, Louie, M, Loeb, MB, Brunton, J, McGeer, AJ; Canadian SARS Research Network, & Kelvin, DJ. (2007). Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol., 81(16), 8692-706. doi: 10.1128/JVI.00527-07. PMID: 17537853;PMCID: PMC1951379.
23. Tang, F, Quan, Y, Xin, ZT, Wrammert, J, Ma, MJ, Lv, H, Wang, TB, Yang, H, Richardus, JH, Liu, W, & Cao, WC. (2011). Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a sixyear follow-up study. J Immunol., 186(12), 7264-8. doi: 10.4049/jimmunol.0903490. PMID: 21576510.
24. Fan, Wu, Aojie Wang, Mei Liu, Qimin Wang, Jun Chen, Shuai Xia, Yun Ling, Yuling Zhang, Jingna Xun, Lu Lu, Shibo Jiang, Hongzhou Lu, Yumei Wen, & Jinghe Huang. (2020). Neutralizing antibody responses to SARSCoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. doi: https://
doi.org/10.1101/2020.03.30.20047365. DOI:10.2139/ssrn.3566211.
25. Lu, R, Zhao, X, Li, J, Niu, P, Yang, B, Wu, H, Wang, W, Song, H, Huang, B, Zhu, N, Bi, Y, Ma, X, Zhan, F, Wang, L, Hu, T, Zhou, H, Hu, Z, Zhou, W, Zhao, L, Chen, J, Meng, Y, Wang, J, Lin, Y, Yuan, J, Xie, Z, Ma, J, Liu, WJ, Wang, D, Xu, W, Holmes, EC, Gao, GF, Wu, G, Chen, W, Shi, W, & Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins andreceptor binding. Lancet, 395(10224), 565-74. DOI: 10.1016/s0140-6736(20)30251-8. PMID: 32007145; PMCID: PMC7159086.
26. Hoffmann, M, Hannah, K-W, Krüger, N, Müller, M, Drosten, C, & Pöhlmann, S. (2020). The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor-ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. DOI:10.1101/2020.01.31.929042. [Preprint].
27. Salazar, E, Kuchipudi, SV, Christensen, PA, Eagar, TN, Yi, X, Zhao, P, Jin, Z, Long, SW, Olsen, RJ, Chen, J, Castillo, B, Leveque, C, Towers, DM, Lavinder, J, Gollihar, JD, Cardona, J, Ippolito, GC, Nissly, RH, Bird, IM, Greenawalt, D, Rossi, RM, Gontu, A, Srinivasan, S, Poojary, IB, Cattadori, IM, Hudson, PJ, Joselyn, N, Prugar, L, Huie, K, Herbert, A, Bernard, DW, Dye, J, Kapur, V, & Musser, JM. (2020). Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma. bioRxiv, 2020 Jun 9:2020.06.08.138990. Preprint. doi: 10.1101/2020.06.08.138990. PMID:32577662; PMCID: PMC7302218.
28. Seesuay W, Jittavisutthikul S, Sae-Lim N, Sookrung N, Sakolvaree Y, Chaicumpa W. Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism. Emerging Microbes Infect. 2018;7(1):41. doi:10.1038/s41426-018-0031-3. [Taylor & Francis Online], [Google Scholar]
29. Widjaja, I, Wang, C, van Haperen, R, GutiérrezÁlvarez, J, van Dieren, B, Okba, NMA, Raj, VS, Li, W, Fernandez-Delgado, R, Grosveld, F, van Kuppeveld, FJM, Haagmans, BL, Enjuanes, L, Drabek, D, & Bosch, BJ. (2019). Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and
functions of the MERS-coronavirus spike glycoprotein. Emerging Microbes Infect., 8(1), 516-530. doi:10.1080/22221751.2019.1597 644. PMID: 30938227; PMCID: PMC6455120.
30. Seesuay, W, Jittavisutthikul, S, Sae-Lim, N, Sookrung, N, Sakolvaree, Y, & Chaicumpa, W. (2018). Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism. Emerging Microbes Infect., 7(1), 41. doi:10.1038/s41426-018-0031-3. PMID: 29568066; PMCID: PMC5864874.31. Goo, J, Jeong, Y, Park, YS, Yang, E, Jung, DI, Rho, S, Park, U, Sung, H, Park, PG, Choi, JA, Seo, SH, Cho, NH, Lee, H, Lee, JM, Kim, JO, & Song, M. (2020). Characterization of novel monoclonal antibodies against MERScoronavirus spike protein. Virus Res., 278, 197863. doi:10.1016/j.virusres.2020.197863. PMID: 31945421.
32. Zeng, LP, Ge, XY, Peng, C, Tai, W, Jiang, S, Du, L, Shi, ZL. (2017). Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci China Life Sci., 60(12), 1399-1402. doi:10.1007/s11427-017-9189-3. PMID: 29134417;PMCID: PMC7089274.
33. Cohen, J. (2020). New coronavirus threat galvanizes scientists. Science, 367(6477), 492-93. doi:10.1126/science.367.6477.492. PMID: 32001631.
34. Dhama, K, Sharun, K, Tiwari, R, Dadar, M, Malik, YS, Singh, KP, & Chaicumpa, W. (2020). COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother., 16(6), 1232-1238. doi: 10.1080/21645515.2020.1735227. PMID: 32186952; PMCID: PMC7103671.
Published
2021-11-28
How to Cite
Lisianyi, M. (2021). ОСОБЛИВОСТІ ГУМОРАЛЬНОГО ІМУНІТЕТУ ПРИ COVID-19 ТА ПЕРСПЕКТИВИ ВИКОРИСТАННЯ ПРОТИВІРУСНИХ АНТИТІЛ В КЛІНІЧНІЙ ПРАКТИЦІ (ОГЛЯД ЛІТЕРАТУРИ). Immunology and Allergy: Science and Practice, (3), 14-22. https://doi.org/10.37321/immunology.2021.3-02